ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bempedoic acid

Also written as “ETC-1002”, “Bempedoic acid” and “180mg of ETC-1002(bempedoic acid)”.

Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Dyslipidemias · Coronary Artery Disease · Hyperlipoproteinemia Type II, led by 6 companies.

Drug pageBempedoic acid: every studyMany companies study it; this page follows only the 33 they lead. All 43 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 27, 202333 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Esperion Therapeutics200 open or runningphase 4since Aug 27, 2023Dec 16, 2010none ahead
Daiichi Sankyoits history only61 open or runningphase 4since Apr 6, 2025Apr 6, 2025Jun 1, 2028phase 3 · NCT07474649
Otsukaits history only30 open or runningphase 3since Jan 4, 2023Mar 2, 2021none ahead
Humanis Saglık Anonim Sirketiits history only20 open or runningphase 1since Apr 4, 2025Apr 4, 2025none ahead
CSPC Pharmaceutical Groupits history only11 open or runningphase 3since May 29, 2026May 29, 2026Jun 30, 2027phase 3 · NCT07623915
Gan & Lee Pharmaceuticalsits history only10 open or runningphase 3since Jan 13, 2025Jan 13, 2025none ahead

Also a collaborator on its studies: Medpace.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Dec 16, 2010.

  1. Apr 26, 2012Phase 2 study in HyperlipidemiasNCT01607294 · 60 enrolled · United States
  2. Dec 14, 20122 phase 2 studies in HypercholesterolemiaNCT01779453, NCT01751984
  3. Sep 6, 2013Phase 2 study in HypercholesterolemiaNCT01941836 · 349 enrolled · United States
  4. Feb 24, 2014Phase 2 study in HypercholesterolemiaNCT02072161 · 133 enrolled · United States
  5. Jun 16, 2014Phase 2 study in HypercholesterolemiaNCT02178098 · 143 enrolled · United States
  6. Jan 12, 2016Phase 2 study in HyperlipidemiasNCT02659397 · 68 enrolled · United States
  7. Jan 20, 2016Phase 3 study in HypercholesterolemiaNCT02666664 · 2,230 enrolled · United States, Canada, Germany and more
  8. Dec 7, 20164 phase 3 studiesNCT02988115, NCT02993406, NCT02991118 and 1 more
  9. Feb 9, 2017Phase 2 study in HypercholesterolemiaNCT03051100 · 63 enrolled · United States
  10. Feb 24, 2017Phase 3 study in HypercholesterolemiaNCT03067441 · 1,462 enrolled · United States
  11. Jun 19, 2017Phase 2 study in HypercholesterolemiaNCT03193047 · 59 enrolled · United States
  12. Nov 6, 2017Phase 3 study in HyperlipidemiasNCT03337308 · 382 enrolled · United States
  13. Jan 12, 2023Phase 2 study in HypercholesterolemiaNCT05694260 · 31 enrolled · United States, Canada, Denmark and more
  14. Aug 27, 2023Phase 4 study in Healthy Lactating WomenNCT06021951 · 16 enrolled · United States

TargetBeta

ACLY →read by rule
“An orally bioavailable prodrug and inhibitor of adenosine triphosphate-citrate lyase (ACL), with anti-hyperlipidemic activity”NCIt, by rule
“ATP-citrate synthase inhibitor”ChEMBL 37, by rule

Studies

All 20 Esperion Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06021951Healthy Lactating Women · United States4CompletedFeb 21, 202416
NCT05694260Hypercholesterolemia · United States, Canada, Denmark and more2CompletedJun 4, 202531
NCT03337308Hyperlipidemias · United States3CompletedJun 18, 2018382
NCT03193047Hypercholesterolemia · United States2CompletedJan 29, 201859
NCT03067441Hypercholesterolemia · United States3CompletedNov 5, 20191,462
NCT03051100Hypercholesterolemia · United States2CompletedJun 1, 201763
NCT03001076Hypercholesterolemia · United States3CompletedJan 11, 2018269
NCT02993406Cardiovascular Diseases · United States, Argentina, Australia and more3CompletedNov 7, 202213,970
NCT02991118Hypercholesterolemia · United States3CompletedAug 22, 2018779
NCT02988115Hypercholesterolemia · United States, Canada3CompletedMar 16, 2018345
NCT02666664Hypercholesterolemia · United States, Canada, Germany and more3CompletedFeb 21, 20182,230
NCT02659397Hyperlipidemias · United States2CompletedJul 201668
NCT02178098Hypercholesterolemia · United States2CompletedMay 22, 2015143
NCT02072161Hypercholesterolemia · United States2CompletedJan 2015133
NCT01941836Hypercholesterolemia · United States2CompletedOct 2014349
NCT01779453Hypercholesterolemia · United States2CompletedAug 201358
NCT01751984Hypercholesterolemia · United States2CompletedMay 1, 201356
NCT01607294Hyperlipidemias · United States2CompletedOct 201260
NCT01485146Safety Evaluation of Escalating Doses · United States1CompletedJan 25, 201224
NCT01262638Dyslipidemias · United States2CompletedAug 23, 2011177

How it is read

Names in the registry

  • “ETC-1002”, 10 entries
  • “Bempedoic acid”, 7 entries
  • “180mg of ETC-1002(bempedoic acid)”, 3 entries
  • “bempedoic acid”, 3 entries
  • “Bempedoic Acid Tablet”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.